IPILIMUMAB
Tracking # 20-802591
$99999.00
There are no ratings for this course
Learn moreCourse overview
IPILIMUMAB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF METASTATIC MELANOMA. IT IS IN THE CTLA-4 MONOCLONAL ANTIBODY CLASS OF MEDICATIONS. THIS ACTIVITY ILLUSTRATES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR IPILIMUMAB AS A VALUABLE AGENT IN THE MANAGEMENT OF METASTATIC MELANOMA AND SEVERAL OTHER TUMORS. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., OFF-LABEL USES, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT FOR MEMBERS OF THE HEALTHCARE TEAM IN THE MANAGEMENT OF PATIENTS WITH METASTATIC MELANOMA AND RELATED CONDITIONS.
Subject areas
This course counts toward the state boards and subject areas below.